Arcturus Therapeutics Holdings (ARCT) Cash from Operations: 2018-2025
Historic Cash from Operations for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Sep 2025 value amounting to -$17.2 million.
- Arcturus Therapeutics Holdings' Cash from Operations rose 27.83% to -$17.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$58.3 million, marking a year-over-year increase of 2.94%. This contributed to the annual value of -$59.7 million for FY2024, which is 230.11% down from last year.
- Per Arcturus Therapeutics Holdings' latest filing, its Cash from Operations stood at -$17.2 million for Q3 2025, which was down 198.02% from -$5.8 million recorded in Q2 2025.
- Over the past 5 years, Arcturus Therapeutics Holdings' Cash from Operations peaked at $160.3 million during Q4 2022, and registered a low of -$49.0 million during Q1 2022.
- Moreover, its 3-year median value for Cash from Operations was -$17.2 million (2025), whereas its average is -$12.4 million.
- As far as peak fluctuations go, Arcturus Therapeutics Holdings' Cash from Operations tumbled by 540.79% in 2021, and later soared by 477.11% in 2022.
- Arcturus Therapeutics Holdings' Cash from Operations (Quarterly) stood at -$42.5 million in 2021, then spiked by 477.11% to $160.3 million in 2022, then crashed by 100.39% to -$629,000 in 2023, then skyrocketed by 54.85% to -$284,000 in 2024, then climbed by 27.83% to -$17.2 million in 2025.
- Its Cash from Operations stands at -$17.2 million for Q3 2025, versus -$5.8 million for Q2 2025 and -$35.1 million for Q1 2025.